Episode
First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer — An Interview with Prof Martin Reck
- Published
- Jun 18, 2026
- Duration seconds
- 2445
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/oncology-today-with-dr-neil-love-1004241/episodes/first-line-and-maintenance-therapy-for-patients-with-extensive-stage-small-cell-lung-cancer-an-interview-with-prof-martin-reck/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/oncology-today-with-dr-neil-love-1004241/first-line-and-maintenance-therapy-for-patients-with-extensive-stage-small-cell-lung-cancer-an-interview-with-prof-martin-reck.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring an interview with Prof Martin Reck, including the following topics: Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00) Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25) Considerations with maintenance therapy for ES-SCLC (9:31) Considerations with immunotherapy for ES-SCLC (13:12) Curability of SCLC with systemic therapy (15:17) Data with chemoimmunotherapy for patients with poor performance status (25:55) Future developments in therapy for SCLC (30:11) Rapid fire: Small Cell 101 (35:45) CME information and select publications